Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
To learn if obinutuzumab in combination with CC-99282 can help to control previously untreated, high tumor burden FL
Trial Details
- NCT ID
- NCT06108232
- Phase
- PHASE2
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Cancer Type
- Lymphoma
- Interventions
- Locations (sample)
- Houston, Texas, United States|29.76328,-95.36327
Key Eligibility Criteria
- Patients must meet the following criteria for study entry:
- Histologically diagnosed follicular lymphoma grade 1-3a
- Have no prior systemic treatment for lymphoma
- Stage II, III or IV disease
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lymphoma Trials on Trialify →